The Clorox Company (CLX) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals moderate positive financial performance, with revenue, gross margin, net income, and EPS all showing year-over-year increases. However, significant risks were highlighted, including economic uncertainties, supply chain disruptions, and regulatory challenges. The lack of strategic initiatives and shareholder return discussions, coupled with no clear management guidance or Q&A insights, balances the positive financials, leading to a neutral sentiment prediction.
Key Financial Performance
Revenue Revenue for Q3 FY '26 was $1.92 billion, representing a 4% increase year-over-year. This growth was driven by strong demand in the Health and Wellness segment and pricing actions taken to offset inflationary pressures.
Gross Margin Gross margin improved to 43.5%, up 150 basis points from the prior year. The improvement was attributed to cost savings initiatives and favorable product mix.
Net Income Net income for the quarter was $210 million, a 7% increase compared to the same period last year. This was due to higher sales and improved operational efficiencies.
Earnings Per Share (EPS) Earnings per share came in at $1.68, up from $1.57 in the prior year, reflecting a 7% increase. The rise was driven by higher net income.
Operating Cash Flow Operating cash flow was $300 million, a 10% increase year-over-year, primarily due to improved working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Potential adverse impacts from economic uncertainties and market conditions were mentioned, which could affect the company's performance.
Supply Chain Disruptions: Risks related to supply chain disruptions were highlighted, which could impact operational efficiency and product availability.
Regulatory Hurdles: Challenges associated with navigating regulatory requirements were discussed, posing potential risks to compliance and operations.
Strategic Execution Risks: Concerns about the successful execution of strategic plans were raised, which could hinder the company's ability to achieve its objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AG Research
Andrea Teixeira
Bank AG
Bellet Executive
CFO Peter
Chairman Luc
Cheang Raymond
Clorox FY
Division Andrea
Division Edward
Division Evercore
Division Lauren
Division Moskow
Division PM
EDT day
Edward Lewis
FY Release
Inc Research
Lauren Lieberman
Lewis Rothschild
Lisah Vice
Luc Bellet
Ms Lisah
PM EDT
Peter Grom
Raymond Associates
Relations Rendle
Rendle CEO
Research Division
Rothschild Co
Securities
conference statement
CLX Transcript
The Clorox Company (CLX) Q3 2026 Earnings Call Transcript
Unknown4-30
The earnings call reveals moderate positive financial performance, with revenue, gross margin, net income, and EPS all showing year-over-year increases. However, significant risks were highlighted, including economic uncertainties, supply chain disruptions, and regulatory challenges. The lack of strategic initiatives and shareholder return discussions, coupled with no clear management guidance or Q&A insights, balances the positive financials, leading to a neutral sentiment prediction.
The Clorox Company (CLX) Presents at Citi's 2026 Global Consumer & Retail Conference 2026 Transcript
Neutral3-9
The Clorox Company (CLX) Presents at Consumer Analyst Group of New York Conference 2026 Prepared Remarks Transcript
Neutral2-19
The Clorox Company (CLX) Q2 2026 Earnings Call Transcript
Unknown2-3
The earnings call summary reveals mixed signals: strong financial performance but weak guidance, disciplined promotional activities, and ERP-related expenses tapering off by Q4. The Q&A section indicates management's focus on innovation and strategic investments. However, concerns about negative volume and pricing, unclear long-term profitability impacts, and limited growth trajectory changes balance the positive elements, resulting in a neutral sentiment.
CLX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
